Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure

Radko Komers, Terry T. Oyama, Douglas R. Beard, Chris Tikellis, Bei Xu, Daniel F. Lotspeich, Sharon Anderson

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Rho-associated kinases (ROCK) are activated in the kidney as well as in cultured cells of diabetic models and have been implicated in renal pathophysiology. To explore whether inhibition of ROCK is protective, we studied its role in a model of accelerated diabetic nephropathy where uninephrectomized rats were made diabetic by streptozotocin. After establishing diabetes, rats were treated with the ROCK inhibitor fasudil continuously or for the final 6 weeks of an 18-week experimental period. The results were compared to similar rats given losartan, an established treatment of clinical and experimental diabetic nephropathy, or a combination of both agents. Vehicle-treated diabetic and non-diabetic uninephrectomized rats served as controls. Diabetes resulted in a rapid development of albuminuria, higher glomerulosclerosis and interstitial fibrosis scores, lower glomerular filtration rates, and increased expression of several molecular markers of diabetic nephropathy. Eighteen weeks of fasudil treatment reduced renal ROCK activity, and ameliorated diabetes-induced structural changes in the kidney and expression of the molecular markers in association with a modest anti-proteinuric effect but no change in blood pressure. Late intervention with fasudil reduced glomerulosclerosis, but did not influence proteinuria. Most effects of fasudil were comparable to those of losartan, although losartan lowered blood pressure and further lowered proteinuria. The combination of both treatments was no different than losartan alone. Thus, ROCK inhibition protected the kidney from diabetic nephropathy even though it did not reduce the blood pressure.

Original languageEnglish (US)
Pages (from-to)432-442
Number of pages11
JournalKidney International
Volume79
Issue number4
DOIs
StatePublished - Feb 2011

Fingerprint

rho-Associated Kinases
Diabetic Nephropathies
Losartan
Blood Pressure
Kidney
Proteinuria
Albuminuria
Streptozocin
Glomerular Filtration Rate
Cultured Cells
Fibrosis
fasudil

Keywords

  • connective tissue growth factor
  • diabetic nephropathy
  • fasudil
  • glomerulosclerosis
  • Rho-associated kinases (ROCK)
  • transforming growth factor-β

ASJC Scopus subject areas

  • Nephrology

Cite this

Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. / Komers, Radko; Oyama, Terry T.; Beard, Douglas R.; Tikellis, Chris; Xu, Bei; Lotspeich, Daniel F.; Anderson, Sharon.

In: Kidney International, Vol. 79, No. 4, 02.2011, p. 432-442.

Research output: Contribution to journalArticle

Komers, Radko ; Oyama, Terry T. ; Beard, Douglas R. ; Tikellis, Chris ; Xu, Bei ; Lotspeich, Daniel F. ; Anderson, Sharon. / Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. In: Kidney International. 2011 ; Vol. 79, No. 4. pp. 432-442.
@article{2791b6e645874f31b0a5632c84b45e6a,
title = "Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure",
abstract = "Rho-associated kinases (ROCK) are activated in the kidney as well as in cultured cells of diabetic models and have been implicated in renal pathophysiology. To explore whether inhibition of ROCK is protective, we studied its role in a model of accelerated diabetic nephropathy where uninephrectomized rats were made diabetic by streptozotocin. After establishing diabetes, rats were treated with the ROCK inhibitor fasudil continuously or for the final 6 weeks of an 18-week experimental period. The results were compared to similar rats given losartan, an established treatment of clinical and experimental diabetic nephropathy, or a combination of both agents. Vehicle-treated diabetic and non-diabetic uninephrectomized rats served as controls. Diabetes resulted in a rapid development of albuminuria, higher glomerulosclerosis and interstitial fibrosis scores, lower glomerular filtration rates, and increased expression of several molecular markers of diabetic nephropathy. Eighteen weeks of fasudil treatment reduced renal ROCK activity, and ameliorated diabetes-induced structural changes in the kidney and expression of the molecular markers in association with a modest anti-proteinuric effect but no change in blood pressure. Late intervention with fasudil reduced glomerulosclerosis, but did not influence proteinuria. Most effects of fasudil were comparable to those of losartan, although losartan lowered blood pressure and further lowered proteinuria. The combination of both treatments was no different than losartan alone. Thus, ROCK inhibition protected the kidney from diabetic nephropathy even though it did not reduce the blood pressure.",
keywords = "connective tissue growth factor, diabetic nephropathy, fasudil, glomerulosclerosis, Rho-associated kinases (ROCK), transforming growth factor-β",
author = "Radko Komers and Oyama, {Terry T.} and Beard, {Douglas R.} and Chris Tikellis and Bei Xu and Lotspeich, {Daniel F.} and Sharon Anderson",
year = "2011",
month = "2",
doi = "10.1038/ki.2010.428",
language = "English (US)",
volume = "79",
pages = "432--442",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure

AU - Komers, Radko

AU - Oyama, Terry T.

AU - Beard, Douglas R.

AU - Tikellis, Chris

AU - Xu, Bei

AU - Lotspeich, Daniel F.

AU - Anderson, Sharon

PY - 2011/2

Y1 - 2011/2

N2 - Rho-associated kinases (ROCK) are activated in the kidney as well as in cultured cells of diabetic models and have been implicated in renal pathophysiology. To explore whether inhibition of ROCK is protective, we studied its role in a model of accelerated diabetic nephropathy where uninephrectomized rats were made diabetic by streptozotocin. After establishing diabetes, rats were treated with the ROCK inhibitor fasudil continuously or for the final 6 weeks of an 18-week experimental period. The results were compared to similar rats given losartan, an established treatment of clinical and experimental diabetic nephropathy, or a combination of both agents. Vehicle-treated diabetic and non-diabetic uninephrectomized rats served as controls. Diabetes resulted in a rapid development of albuminuria, higher glomerulosclerosis and interstitial fibrosis scores, lower glomerular filtration rates, and increased expression of several molecular markers of diabetic nephropathy. Eighteen weeks of fasudil treatment reduced renal ROCK activity, and ameliorated diabetes-induced structural changes in the kidney and expression of the molecular markers in association with a modest anti-proteinuric effect but no change in blood pressure. Late intervention with fasudil reduced glomerulosclerosis, but did not influence proteinuria. Most effects of fasudil were comparable to those of losartan, although losartan lowered blood pressure and further lowered proteinuria. The combination of both treatments was no different than losartan alone. Thus, ROCK inhibition protected the kidney from diabetic nephropathy even though it did not reduce the blood pressure.

AB - Rho-associated kinases (ROCK) are activated in the kidney as well as in cultured cells of diabetic models and have been implicated in renal pathophysiology. To explore whether inhibition of ROCK is protective, we studied its role in a model of accelerated diabetic nephropathy where uninephrectomized rats were made diabetic by streptozotocin. After establishing diabetes, rats were treated with the ROCK inhibitor fasudil continuously or for the final 6 weeks of an 18-week experimental period. The results were compared to similar rats given losartan, an established treatment of clinical and experimental diabetic nephropathy, or a combination of both agents. Vehicle-treated diabetic and non-diabetic uninephrectomized rats served as controls. Diabetes resulted in a rapid development of albuminuria, higher glomerulosclerosis and interstitial fibrosis scores, lower glomerular filtration rates, and increased expression of several molecular markers of diabetic nephropathy. Eighteen weeks of fasudil treatment reduced renal ROCK activity, and ameliorated diabetes-induced structural changes in the kidney and expression of the molecular markers in association with a modest anti-proteinuric effect but no change in blood pressure. Late intervention with fasudil reduced glomerulosclerosis, but did not influence proteinuria. Most effects of fasudil were comparable to those of losartan, although losartan lowered blood pressure and further lowered proteinuria. The combination of both treatments was no different than losartan alone. Thus, ROCK inhibition protected the kidney from diabetic nephropathy even though it did not reduce the blood pressure.

KW - connective tissue growth factor

KW - diabetic nephropathy

KW - fasudil

KW - glomerulosclerosis

KW - Rho-associated kinases (ROCK)

KW - transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=79551507167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551507167&partnerID=8YFLogxK

U2 - 10.1038/ki.2010.428

DO - 10.1038/ki.2010.428

M3 - Article

C2 - 20962741

AN - SCOPUS:79551507167

VL - 79

SP - 432

EP - 442

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -